'The molecule, called a monoclonal antibody, is being readied for human clinical trials for CLL "in the not-too-distant future," said lead researcher Thomas J. Kipps in a statement on the results.
Kipps holds the Evelyn and Edwin Tasch Chair in Cancer Research ath the UCSD Moores Cancer Center.'
'Named RG7356, the "humanized" monoclonal antibody targets a receptor or surface molecule, called CD44, found on the CLL cells. The antibody is toxic to the cells, according to laboratory studies.'
Article
utsandiego.com/news/2013/ma...
FULL PAPER